Adicet Bio/$ACET
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Adicet Bio
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Ticker
$ACET
Sector
Primary listing
Employees
102
Headquarters
Website
Adicet Bio Metrics
BasicAdvanced
$74M
-
-$16.95
1.61
-
Price and volume
Market cap
$74M
Beta
1.61
52-week high
$9.05
52-week low
$6.41
Average daily volume
160K
Financial strength
Current ratio
7.474
Quick ratio
7.379
Long term debt to equity
7.256
Total debt to equity
9.257
Interest coverage (TTM)
-3,392.06%
Profitability
EBITDA (TTM)
-115.733
Management effectiveness
Return on assets (TTM)
-37.00%
Return on equity (TTM)
-67.55%
Valuation
Price to book
0.47
Price to tangible book (TTM)
0.47
Price to free cash flow (TTM)
-0.492
Free cash flow yield (TTM)
-203.37%
Free cash flow per share (TTM)
-14.073
Growth
Earnings per share change (TTM)
-20.53%
3-year earnings per share growth (CAGR)
-14.57%
Adicet Bio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Adicet Bio stock?
Adicet Bio (ACET) has a market cap of $74M as of March 23, 2026.
What is the P/E ratio for Adicet Bio stock?
The price to earnings (P/E) ratio for Adicet Bio (ACET) stock is 0 as of March 23, 2026.
Does Adicet Bio stock pay dividends?
No, Adicet Bio (ACET) stock does not pay dividends to its shareholders as of March 23, 2026.
When is the next Adicet Bio dividend payment date?
Adicet Bio (ACET) stock does not pay dividends to its shareholders.
What is the beta indicator for Adicet Bio?
Adicet Bio (ACET) has a beta rating of 1.61. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.